Class Central is learner-supported. When you buy through links on our site, we may earn an affiliate commission.

Stanford University

Project ECHO Diabetes in the Time of COVID-19: DPP-4 Inhibitor, GLP-1 Receptor Agonist, & SGLT Inhibitor Therapies (Recorded Webinar)

Stanford University via Independent

Overview

Save Big on Coursera Plus. 7,000+ courses at $160 off. Limited Time Only!
Stanford Center for Continuing Medical Education, Project ECHO Diabetes in the Time of COVID-19: DPP-4 Inhibitor, GLP-1 Receptor Agonist, & SGLT Inhibitor Therapies (Recorded Webinar), 7/21/2020 12:00:00 AM - 7/21/2023 12:00:00 AM, This activity will address the urgent needs of patients with type 1 and type 2 diabetes who require complex diabetes treatment in the primary care setting in the time of COVID-19 by empowering and increasing the capacity of primary care providers (PCPs) and clinics to safely and effectively manage underserved patients who do not have access to routine specialty care. Led by a nationally/internationally renowned faculty team of diabetes experts (many of whom contribute to/co-author national guideline recommendations), this curriculum will spotlight various aspects of diabetes management for patients at high-risk for poor outcomes during the time of COVID-19.

Reviews

Start your review of Project ECHO Diabetes in the Time of COVID-19: DPP-4 Inhibitor, GLP-1 Receptor Agonist, & SGLT Inhibitor Therapies (Recorded Webinar)

Never Stop Learning.

Get personalized course recommendations, track subjects and courses with reminders, and more.

Someone learning on their laptop while sitting on the floor.